Efficacy of amoxycillin versus amoxycillin/clavulanate in acute exacerbations of chronic pulmonary obstructive disease in primary care
BACKGROUND: Amoxycillin/clavulanate is considered first-line treatment for ambulatory exacerbations of COPD. However, narrow-spectrum antibiotics may be as useful for mild to moderate patients.
OBJECTIVE: To compare the clinical efficacy of amoxycillin versus amoxicyllin/clavulanate in exacerbations of COPD in primary care.
METHODS: A randomized, double-blind, noninferiority clinical trial was carried out in eight primary care centers in Catalonia, Spain. Spirometrically-diagnosed patients older than 40 years with COPD, without criteria of hospitalization and Anthonisen's types I or II exacerbations were included. The main outcome was clinical cure at the end of treatment (EOT) visit on day 10.
RESULTS: A total of 137 patients were enrolled in the study (68 assigned to amoxycillin and 69 to amoxycillin/clavulanate). The mean forced expiratory flow in one second was 61.6% and the mean age was 71.4 years. At EOT, 92.8% of patients in the amoxycillin/clavulanate and 90.9% in the amoxycillin group were considered clinically cured, a statistically non-significant difference. Adverse effects were observed in 11 subjects, 3 in the amoxycillin group and 8 in the amoxycillin/clavulanate group, 2 of whom required a change in treatment.
CONCLUSIONS: Amoxycillin was at least as effective clinically and as safe as amoxycilin/ clavulanate in the treatment of acute exacerbations of COPD in mild to moderate patients in primary care.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2009 |
|---|---|
| Erschienen: |
2009 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
International journal of chronic obstructive pulmonary disease - 4(2009) vom: 15., Seite 45-53 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Llor, Carl [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 04.02.2010 Date Revised 20.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM188474595 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM188474595 | ||
| 003 | DE-627 | ||
| 005 | 20231223182000.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2009 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0628.xml |
| 035 | |a (DE-627)NLM188474595 | ||
| 035 | |a (NLM)19436696 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Llor, Carl |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy of amoxycillin versus amoxycillin/clavulanate in acute exacerbations of chronic pulmonary obstructive disease in primary care |
| 264 | 1 | |c 2009 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.02.2010 | ||
| 500 | |a Date Revised 20.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Amoxycillin/clavulanate is considered first-line treatment for ambulatory exacerbations of COPD. However, narrow-spectrum antibiotics may be as useful for mild to moderate patients | ||
| 520 | |a OBJECTIVE: To compare the clinical efficacy of amoxycillin versus amoxicyllin/clavulanate in exacerbations of COPD in primary care | ||
| 520 | |a METHODS: A randomized, double-blind, noninferiority clinical trial was carried out in eight primary care centers in Catalonia, Spain. Spirometrically-diagnosed patients older than 40 years with COPD, without criteria of hospitalization and Anthonisen's types I or II exacerbations were included. The main outcome was clinical cure at the end of treatment (EOT) visit on day 10 | ||
| 520 | |a RESULTS: A total of 137 patients were enrolled in the study (68 assigned to amoxycillin and 69 to amoxycillin/clavulanate). The mean forced expiratory flow in one second was 61.6% and the mean age was 71.4 years. At EOT, 92.8% of patients in the amoxycillin/clavulanate and 90.9% in the amoxycillin group were considered clinically cured, a statistically non-significant difference. Adverse effects were observed in 11 subjects, 3 in the amoxycillin group and 8 in the amoxycillin/clavulanate group, 2 of whom required a change in treatment | ||
| 520 | |a CONCLUSIONS: Amoxycillin was at least as effective clinically and as safe as amoxycilin/ clavulanate in the treatment of acute exacerbations of COPD in mild to moderate patients in primary care | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Amoxicillin-Potassium Clavulanate Combination |2 NLM | |
| 650 | 7 | |a 74469-00-4 |2 NLM | |
| 650 | 7 | |a Amoxicillin |2 NLM | |
| 650 | 7 | |a 804826J2HU |2 NLM | |
| 700 | 1 | |a Hernández, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Ribas, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Alvarez, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Cots, Josep Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Bayona, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a González, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Miravitlles, Marc |e verfasserin |4 aut | |
| 700 | 0 | |a BRAMOX Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Ansa, Xabier |e investigator |4 oth | |
| 700 | 1 | |a Bonamaison, Montse |e investigator |4 oth | |
| 700 | 1 | |a Cereceda, Marta |e investigator |4 oth | |
| 700 | 1 | |a Deniel, Joan |e investigator |4 oth | |
| 700 | 1 | |a Espina, Jordi |e investigator |4 oth | |
| 700 | 1 | |a Espinàs, Jordi |e investigator |4 oth | |
| 700 | 1 | |a Ezquerra, Teresa |e investigator |4 oth | |
| 700 | 1 | |a Gifré, Josep M |e investigator |4 oth | |
| 700 | 1 | |a Grifoll, Ferran |e investigator |4 oth | |
| 700 | 1 | |a Pedrerol, M Mar |e investigator |4 oth | |
| 700 | 1 | |a Planes, Albert |e investigator |4 oth | |
| 700 | 1 | |a Pujol, Xavier |e investigator |4 oth | |
| 700 | 1 | |a Ribas, Montserrat |e investigator |4 oth | |
| 700 | 1 | |a Rodríguez, Anna |e investigator |4 oth | |
| 700 | 1 | |a Salla, Rosa M |e investigator |4 oth | |
| 700 | 1 | |a Valldosera, Jordi |e investigator |4 oth | |
| 700 | 1 | |a Vilajoana, Meritxell |e investigator |4 oth | |
| 700 | 1 | |a Vilamú, Maria |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of chronic obstructive pulmonary disease |d 2006 |g 4(2009) vom: 15., Seite 45-53 |w (DE-627)NLM175408165 |x 1178-2005 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2009 |g day:15 |g pages:45-53 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2009 |b 15 |h 45-53 | ||